Biodexa Pharmaceuticals Reports 2025 Losses, Advances Pipeline with MTX240 License
Event summary
- Biodexa reported a £6.38 million loss for 2025, down from £5.73 million in 2024, with R&D costs decreasing 27% to £3.96 million.
- The company secured a $10 million financing in December 2025 and has $26.08 million undrawn from a $35 million ELOC.
- Biodexa licensed MTX240 from Otsuka in February 2026 for GIST treatment, with plans to initiate a Phase 1b/2a study by year-end.
- The Phase 3 Serenta trial for eRapa in FAP enrolled 37 patients as of March 2026, with database lock expected in late 2029.
- Tolimidone's Phase 2a study in T1D is ongoing, with first patient enrolled in June 2025.
The big picture
Biodexa's 2025 results highlight the financial challenges of clinical-stage biotech companies, even as it advances its pipeline with strategic licensing deals. The MTX240 license from Otsuka represents a pivot toward gastrointestinal and oncology programs, but the company's ability to execute on these initiatives hinges on securing non-dilutive financing. The broader biotech sector faces similar pressures, with small-cap firms struggling to balance R&D spending against the need for capital.
What we're watching
- Financial Sustainability
- Whether Biodexa can secure additional financing by Q3 2026 to sustain operations until milestone payments or royalties materialize.
- Clinical Progress
- The pace at which the Phase 3 Serenta trial for eRapa and the upcoming Phase 1b/2a study for MTX240 advance, given the company's resource constraints.
- Pipeline Expansion
- How successfully Biodexa can develop additional indications for tolimidone beyond T1D, given its preclinical potential.
Related topics